Provided by Tiger Trade Technology Pte. Ltd.

Arrowhead Pharmaceuticals

70.67
-10.0000-12.40%
Pre-market: 71.250.5800+0.82%06:11 EDT
Volume:4.37M
Turnover:321.71M
Market Cap:9.95B
PE:-30.94
High:83.55
Open:82.89
Low:70.61
Close:80.67
52wk High:95.49
52wk Low:28.48
Shares:140.86M
Float Shares:122.00M
Volume Ratio:2.45
T/O Rate:3.58%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-2.2838
EPS(LYR):-0.0122
ROE:-55.21%
ROA:-8.10%
PB:21.38
PE(LYR):-5,795.95

Loading ...

Sector Update: Healthcare Stocks Softer Late Afternoon

MT Newswires Live
·
Jul 23

Arrowhead Pharmaceuticals is Maintained at Buy by Chardan Capital

Dow Jones
·
Jul 23

Top Midday Gainers

MT Newswires Live
·
Jul 23

Arrowhead Pharma Shares Rise After Positive Results for Triglyceride Drug Plozasiran Trials

Dow Jones
·
Jul 23

Arrowhead price target raised to $115 from $90 at Chardan

TIPRANKS
·
Jul 23

Arrowhead Pharmaceuticals (ARWR) Stock Soars on Strong Phase 3 Trial Results

TIPRANKS
·
Jul 23

Arrowhead rises 23.4%

TIPRANKS
·
Jul 23

Analysts Are Bullish on These Healthcare Stocks: Arrowhead Pharmaceuticals (ARWR), Otsuka Holdings Co (OTSKY)

TIPRANKS
·
Jul 22

U.S. Stocks on the Move-ge Vernova, Arrowhead Pharma

Reuters
·
Jul 22

Movement Alert|Arrowhead Pharmaceuticals Rises 19.25% in Regular Trading, Core Pipeline Plozasiran Achieves Key Late-Stage Trial Endpoints

Market Focus
·
Jul 22

Arrowhead Pharmaceuticals Shares up 18.1% Premarket After Blood-fat Drug Meets Late-stage Trial Goals

THOMSON REUTERS
·
Jul 22

Arrowhead Rises After Blood-fat Drug Meets Late-stage Trial Goals

Reuters
·
Jul 22

Movement Alert|Arrowhead Pharmaceuticals Rises 8.64% in Pre-Market Trading, Core Pipeline Plozasiran Delivers Strong Results Across Multiple Key Trials

Market Focus
·
Jul 22

Arrowhead Pharma Announces Press Release on Plozasiran Phase 3 Shasta-3 and Shasta-4 Topline Results

Reuters
·
Jul 22

Arrowhead Pharmaceuticals - Plozasiran Shows Significant Reduction in Acute Pancreatitis Events, 100% in High-risk Patients

THOMSON REUTERS
·
Jul 22

Arrowhead Pharmaceuticals - Plozasiran Demonstrates Consistent Safety Profile with no New Safety Signals

THOMSON REUTERS
·
Jul 22

Arrowhead Pharmaceuticals - Plozasiran Achieves 79% and 81% Median Triglyceride Reduction in Shasta-3 and Shasta-4

THOMSON REUTERS
·
Jul 22

Arrowhead Pharmaceuticals - to File Supplemental Nda for Plozasiran with U.S. FDA Before End of 2026

THOMSON REUTERS
·
Jul 22

Press Release: Arrowhead Pharmaceuticals to Webcast Fiscal 2026 Third Quarter Results

Dow Jones
·
Jul 21

Is Arrowhead Pharmaceuticals (ARWR) Undervalued Or Is Its Pipeline Promise Already Priced In?

Simply Wall St.
·
Jul 18